Table 5.
Overall product satisfaction at Day 28 (end of study).
| ITT |
BMF≤3/week |
||||||||
| |
Total |
High dose |
Low dose |
Placebo |
Total |
High dose |
Low dose |
Placebo |
|
| Not at all satisfied | 38 (16.7%) | 13 (17.1%) | 13 (17.1%) | 12 (15.8%) | 13 (20.0%) | 5 (26.3%) | 3 (13.0%) | 5 (21.7%) | |
| A little satisfied | 39 (17.1%) | 12 (15.8%) | 15 (19.7%) | 12 (15.8%) | 13 (20.0%) | 3 (15.8%) | 6 (26.1%) | 4 (17.4%) | |
| Moderately satisfied | 59 (25.9%) | 16 (21.1%) | 21 (27.6%) | 22 (28.9%) | 16 (24.6%) | 2 (10.5%) | 7 (30.4%) | 7 (30.4%) | |
| Quite satisfied | 60 (26.3%) | 24 (31.6%) | 14 (18.4%) | 22 (28.9%) | 19 (29.2%) | 8 (42.1%) | 4 (17.4%) | 7 (30.4%) | |
| Very satisfied | 28 (12.3%) | 9 (11.8%) | 11 (14.5%) | 8 (10.5%) | 4 (6.2%) | 1 (5.3%) | 3 (13.0%) | — | |
BMF≤3/week, participants from the ITT population who had fewer than or equal to 3 bowel movements per week during the entire 14-day run-in period; high-dose group, 1 × 1010 CFU of HN019/day; ITT, intention-to-treat population—all participants randomized at the second visit who consumed at least 1 dose of the study product; low-dose group 1 × 109 CFU of HN019/day. ‘-‘, no value. Values are number of participants (%).